HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Metyrosine

HCID 441350
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
672-87-7
Standard SMILES
C[C@](N)(Cc1ccc(O)cc1)C(=O)O
InChIKey
NHTGHBARYWONDQ-JTQLQIEISA-N
Molecular formula
C10H13NO3
Average molar mass
195.21 g/mol
Monoisotopic mass
195.08954328

Overview

Alpha-methyl-L-tyrosine is an L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. It has a role as an antihypertensive agent and an EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor. It is a L-tyrosine derivative and a non-proteinogenic L-alpha-amino acid.

Names & identifiers

Preferred name
Metyrosine
IUPAC
(2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
English name
alpha-Methyl-L-p-tyrosine
Molecular formula
C10H13NO3
Molecular weight
195.22

Names & synonyms

METYROSINE672-87-7MetirosineDemserMetirosina(2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid(S)-alpha-MethyltyrosineL-alpha-MethyltyrosineMetirosinum(-)-alpha-Methyl-L-tyrosineAlpha-Methyl-L-P-TyrosineMK-781
Show more names
α-Methyl-L-tyrosineα-Me-Tyr-OHAMPTL-AMPTL-α-MTa-Me-Tyr-OHL-Metyrosine
DTXSID6023315DOQ0J0TPF7CHEBI:6912L-588357-0DTXCID203315methyl-tyrosineRefChem:56543alpha-Methyltyrosine, (L)-

Database identifiers

CAS
672-87-7
PubChem CID
441350
DTXSID
DTXSID6023315
ChEMBL
CHEMBL1200862
ChEBI
CHEBI:6912
UNII
DOQ0J0TPF7
EC Number
211-599-5
Nikkaji
J9.465J

Properties

Computed structural properties

XLogP
-1.6
Topological polar surface area
83.6 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
4
Rotatable bonds
3
Heavy atoms
14
Formal charge
0
Complexity
211

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LogP-1.7
Solubility · 2 items

Very slightly soluble

2.48e+00 g/L

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point312.5 °C
Physical DescriptionSolid

Physicochemical properties

Melting point
320 · 320-340°C dec.
Boiling point
383.7 · 383.7±32.0 °C(Predicted)
Density
1.283 · 1.283±0.06 g/cm3(Predicted)
storage temp.
-20 °C · -20°C
solubility
Aqueous Acid (Slightly)
form

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P301+P317, P304+P340, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Metyrosine

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Safety data

PPE
Eyeshields, Gloves, type N95 (US)
wgk
3
tsca
No
hs_code
2922504500
risk_code
22-38-40-48/20/22
Signal word
Warning
Symbol(GHS)
GHS07
safety_code
22-24/25
Storage Class
11 - Combustible Solids
Hazard statements
H315-H319
Precautionary statements

Chemistry & industry

Pharmacology

ATC Code · 2 items

C - Cardiovascular system

QC - Cardiovascular system

Pharmacodynamics · 1 item

In patients with pheochromocytoma, who produce excessive amounts of norepinephrine and epinephrine, administration of one to four grams of metyrosine per day has reduced catecholamine biosynthesis from about 35 to 80 percent as measured by the total excretion of catecholamines and their metabolites (metanephrine and vanillylmandelic acid). The maximum biochemical effect usually occurs within two to three days, and the urinary concentration of catecholamines and their metabolites usually returns to pretreatment levels within three to four days after metyrosine is discontinued. Most patients with pheochromocytoma treated with metyrosine experience decreased frequency and severity of hypertensive attacks with their associated headache, nausea, sweating, and tachycardia. In patients who respond, blood pressure decreases progressively during the first two days of therapy with metyrosine; after withdrawal, blood pressure usually increases gradually to pretreatment values within two to three days.

Mechanism of Action · 1 item

Metyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines and their synthesis. This consequently, depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body,usually measured as decreased urinary excretion of catecholamines and their metabolites. One main end result of the catecholamine depletion is a decrease in blood presure.

Biological Half-Life3.4 to 3.7 hours
Metabolism/MetabolitesLittle biotransformation, with catechol metabolites accounting for less than 1% of the administered dose.
FDA Pharmacological Classification · 6 items

Related reactions

5 records
New reaction record
HRID 78951 reaction equation
HRID 78951As product
HRID 78954 reaction equation
HRID 78954As product
HRID 1980390 reaction equation
HRID 1980390As product
HRID 2230273 reaction equation
HRID 2230273As reactant
HRID 2289418 reaction equation
HRID 2289418As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Powder
pka
2.7 · pKa 2.7 (Uncertain);10.1 (Uncertain)
color
White to pale yellow
optical activity
-3.6 ° · -3.60°(C=0.01g/ml 1N HCL)
Merck
13 · 13,6183
BRN
2368400 · 2368400
InChI
InChI=1/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/s3
InChIKey
NHTGHBARYWONDQ-JTQLQIEISA-N
SMILES
C(C1C=CC(O)=CC=1)[C@@](N)(C)C(=O)O |&1:8,r|
CAS DataBase Reference
672 · 672-87-7(CAS DataBase Reference)
FDA UNII
0 J0TPF7 · DOQ0J0TPF7
NCI Drug Dictionary
DEMSER
ATC code
2 KB01 · C02KB01
UNSPSC Code
41116107 · 41116107
NACRES
32 · NA.32
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
315 · H315-H319
Precautionary statements
261 · P261-P281-P305+P351+P338
PPE
95 · Eyeshields, Gloves, type N95 (US)
Risk Statements
22 · 22-38-40-48/20/22
Safety Statements
22 · 22-24/25
WGK Germany
3 · 3
TSCA
No
HS Code
2922504500 · 2922504500
Storage Class
11 · 11 - Combustible Solids
P261-P281-P305+P351+P338

DOQ0J0TPF7

METYROSINE

Established Pharmacologic Class [EPC] - Catecholamine Synthesis Inhibitor

Mechanisms of Action [MoA] - Catecholamine Synthesis Inhibitors

Metyrosine is a Catecholamine Synthesis Inhibitor. The mechanism of action of metyrosine is as a Catecholamine Synthesis Inhibitor.

METYROSINE

MeSH Pharmacological ClassificationCompounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Absorption, Distribution and Excretion · 2 items

Well absorbed from the gastrointestinal tract.

Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.

Applications · 4 items

Usesα-Methyl-L-tyrosine is used to determine whether Fe2/ methamphetamine (METH) -induced cell death is dependent on cytosolic dopamine and iron mediated oxidative stress.

UsesMetyrosine is the α-methyl derivative of tyrosine. It competitively inhibits tyrosine hydroxylase action, thus reducing the formation of epinephrine and norepinephrine. It is used for treating patients with pheochromocytoma, in cases where a rise in the level of catecholamines is observed.

UsesA tyrosine hydroxylase inhibitor. An antihypertensive in pheochromocytoma

General DescriptionMetyrosine (α-Methyl-L-tyrosine, Demser). Althoughinhibition of any of the three enzymes involved in CA biosynthesisshould decrease CAs, inhibitors of the first andthe rate-limiting enzyme TH would be the most effective.As such, metyrosine is a much more effective competitiveinhibitor of E and NE production than agents that inhibitany of the other enzymes involved in CA biosynthesis. Itis often possible to “fool” the enzymes into accepting astructurally similar and unnatural substrate such as metyrosine.Metyrosine differs structurally from tyrosine onlyin the presence of an α-methyl group . It is oneexample of a CA-biosynthesis inhibitor in clinical use.Although metyrosine is used as a racemic mixture, it is the (-)isomer that possesses the inhibitory activity.Metyrosine, which is given orally in dosages ranging from 1 to 4 g/day, is used principally for the preoperative managementof pheochromocytoma, chromaffin cell tumorsthat produce large amounts of NE and E. Although theseadrenal medullary tumors are often benign, patients frequentlysuffer hypertensive episodes. Metyrosine reducesthe frequency and severity of these episodes by significantlylowering CA production (35%–80%). The drug ispolar (log P=0.73) and excreted mainly unchanged in theurine. Because of its limited solubility in water caused byintramolecular bonding of the zwitterions, crystalluria is apotential serious side effect. It can be minimized by maintaininga daily urine volume of more than 2 L. Inhibitors ofCA synthesis have limited clinical utility because suchagents nonspecifically inhibit the formation of all CAs andresult in many side effects. Sedation is the most commonside effect of this drug.A similar example is the use of α-methyl-m-tyrosine inthe treatment of shock. It differs structurally from metyrosineonly in the presence of m-OH instead of p-OH inmetyrosine. This unnatural amino acid is accepted by the enzymesof the biosynthetic pathway and converted tometaraminol (an α-agonist).

Additional notes · 1 item

DefinitionChEBI: An L-tyrosine derivative that consists of L-tyrosine bering an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is us d to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.